IL2 and capillary leak syndrome: IL-2 is a typical example of cytokine therapies and was approved by FDA for treating metastatic renal cell carcinoma in 1992, while the significant toxicities including capillary leak syndrome and multiple organ dysfunction limit the use of IL-2 (71).